SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The September 2024 quarter revenue stood at Rs. 26360.99 millions, up 18.03% as compared to Rs. 22334.16 millions during the corresponding quarter last year.Net profit surges 96.81% to Rs. 5950.56  millions  from Rs. 3023.54 millions in the quarter ended September 2024.Operating profit for the quarter ended September 2024 rose to 8617.03 millions as compared to 5170.68 millions of corresponding quarter ended September 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 26360.99 22334.16 18.03 49656.36 43778.00 13.43 78911.19 82206.62 -4.01
Other Income 830.77 735.78 12.91 1387.25 1229.39 12.84 11680.24 9859.39 18.47
PBIDT 8617.03 5170.68 66.65 15484.53 10514.25 47.27 24096.87 24587.06 -1.99
Interest 117.95 581.87 -79.73 271.44 1201.21 -77.40 2771.10 2068.16 33.99
PBDT 8499.08 4392.12 93.51 15213.09 8800.06 72.87 72029.08 17560.22 310.18
Depreciation 548.49 498.46 10.04 1079.36 985.98 9.47 2021.62 1841.48 9.78
PBT 7950.59 3893.66 104.19 14133.73 7814.08 80.88 70007.46 15718.74 345.38
TAX 2000.03 870.12 129.86 3645.86 2073.98 75.79 18334.55 3631.05 404.94
Deferred Tax 615.40 777.97 -20.90 1181.39 1596.18 -25.99 7834.63 -238.26 -3388.27
PAT 5950.56 3023.54 96.81 10487.87 5740.10 82.71 51672.91 12087.69 327.48
Equity 282.19 282.17 0.01 282.19 282.17 0.01 282.19 282.17 0.01
PBIDTM(%) 32.69 23.15 41.19 31.18 24.02 29.84 30.54 29.91 2.10

Glenmark Pharma Share Price

2364.35 -6.70 (-0.28%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×